mydrugindex
Kenyan Reference & Directory
Free lookups today: 0/3 · Unlimited with Pro Subscribe from KES 99
Free lookups: 0/3 Unlimited with Pro → Browse by class Interactions · Tip: type at least 2 letters, then pick a result

INN monograph

Naloxone

Therapeutic agent (verify pharmacological class) · POM

POM

Verified · Updated 01 Aug 2026 · Source: Local active-ingredient clinical extract; RxNorm (NLM RxNav); PubChem; Professional class pharmacology (Therapeutic agent (verify pharmacological class))

Class
Therapeutic agent (verify pharmacolo...
Schedule
POM
Route
See product SmPC
Onset
Product-specific
Duration
Product-specific
Pregnancy
Use only if potential be...
Renal
Review renal impairment...
High-alert
No

Kenya market

Wholesale / list prices where loaded

From
Median
Brands
2

Risk first

Contraindications

  • Hypersensitivity to the active substance or excipients.
  • Additional absolute contraindications are indication- and product-specific — consult SmPC.

Precautions

  • Acute withdrawal syndrome may arise in opiod dependent patients after rapid reversal
  • avoid use in opioid dependent pregnant women as it can cause withdrawal syndrome in fetus.

Point of care

Dosing

Adult

Adult: Initial dose of 0.4-2mg, IV [or IM or SC when IV is not available]. If the desired effects are not attained repeat at 2-3 minute interval [up to 10mg]. Children & neonates: 0.01 mg/kg I.V. A subsequent dose of 0.1 mg/kg may be administered if the response is not satisfactory.

Paediatric

See label paediatric section if present; otherwise use paediatric formulary — do not extrapolate adult doses.

Renal

Review renal impairment dosing; many agents need CrCl/eGFR adjustment.

  • CrCl 0–120: Confirm renal dosing in product SmPC / primary label.

Hepatic

Review hepatic impairment dosing; monitor LFTs if agent is hepatically cleared or hepatotoxic.

Safety

Drug interactions

Open checker →
  • Professional use: confirm indication, dose, duration, monitoring and patient counselling points against current Kenya STG / EML and the product SmPC.
  • Document allergy status and key interactions.

Safety

Adverse effects

  • Adverse reactions vary by agent.
  • Counsel on common predictable effects and serious warning symptoms (allergy, severe rash, jaundice, unusual bleeding, severe GI symptoms, neurological changes).
  • Report suspected ADRs via national pharmacovigilance channels.

Use

Indications

  • Complete or partial reversal of opioid depression including respiratory depression
  • diagnosis of suspected or known acute opioid overdosage
  • as an adjunctive agent to increase blood pressure in the management of septic shock
  • reversal of opioid sedation after anaesthesia
  • Reversal of sedation and respiratory depression in neonate after maternal exposure to opioids.

Pharmacology

Mode of action

It is known to be an opioid antagonist that competes for the [with greatest affinity], and opiate receptor sites in the CNS.

It is known to be an opioid antagonist tha… Mechanism is agent-specific. At receptor, enzyme, ion channel, transpor…
Full mechanism text

It is known to be an opioid antagonist that competes for the [with greatest affinity], and opiate receptor sites in the CNS. Mechanism is agent-specific. At receptor, enzyme, ion channel, transporter or microbial target level, the drug alters a physiological or pathological pathway to produce its therapeutic effect. Confirm precise molecular mechanism in current SmPC / pharmacology reference for this INN before high-stakes decisions.

ADME

Pharmacokinetics & PD

Onset Product-specific
Duration Product-specific
Route See product SmPC
Elimination are product-specific. Consider food effects, protein binding, hepatic CYP/UGT
Half-life when adjusting for organ impairment, age and drug interactions. Verify parameters in the current SmPC.
Full PK/PD text

Absorption, distribution, metabolism and excretion are product-specific. Consider food effects, protein binding, hepatic CYP/UGT metabolism, renal clearance and half-life when adjusting for organ impairment, age and drug interactions. Verify parameters in the current SmPC.

Kenya

Brands & prices

2 listed
Brand Company Pack KES
Nalotas, Tasa Independent / Registered Supplier Standard Commercial Pack
Naloxone Rotex Medical Standard Commercial Pack

Special populations

Pregnancy & lactation

Pregnancy

Use only if potential benefit justifies potential risk; prefer agents with better reproductive data when alternatives exist.

Lactation

Assess infant risk vs benefit of maternal therapy; prefer agents with lactation data.

Diet

Food & alcohol

  • Food
  • Food

Trust

Sources & disclaimer

Source: Local active-ingredient clinical extract; RxNorm (NLM RxNav); PubChem; Professional class pharmacology (Therapeutic agent (verify pharmacological class))

Open source link

Last reviewed: 01 Aug 2026

Decision support only — not a substitute for clinical judgment, product SmPC, or Kenya STG/EML.

Kenya Verified Health Registry